"PADRES" (Prior Axitinib as a Determinant of Outcome of REnal Surgery)
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PADRES
- 19 Sep 2018 Planned primary completion date changed from 29 Oct 2018 to 29 Oct 2019.
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.
- 22 Feb 2018 New trial record